Trial Profile
A Randomized Phase II Trial of Deforolimus (AP23573; MK-8669) Compared to Progestin in Female Adult Patients With Advanced Endometrial Carcinoma Following One Line of Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary) ; Carboplatin; Doxorubicin; Doxorubicin liposomal; Medroxyprogesterone; Megestrol; Paclitaxel; Topotecan
- Indications Carcinoma; Clear cell sarcoma; Endometrial cancer; Sarcoma
- Focus Therapeutic Use
- Sponsors ARIAD Pharmaceuticals; Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 19 Jun 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
- 10 Aug 2012 Additional lead trial investigator identified as reported by UKCRN.
- 09 Aug 2012 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.